A PYMNTS Company

UK: Drugmakers admit to colluding

By  |  September 23, 2019

The move comes as part of a competition law investigation by the Competition and Markets Authority (CMA) into drug firms King Pharmaceuticals Limited, Alissa Healthcare Research Limited and Lexon (UK) Limited.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    In June 2019, the CMA issued a statement of objections provisionally finding that the 3 suppliers had exchanged commercially sensitive information about prices, volumes and entry plans in order to keep prices up.

    Nortriptyline is prescribed by the NHS and relied on by thousands of patients every month to relieve the symptoms of depression. NHS spending on the drug peaked at £38 million in 2015.

    Full Content: Gov UK

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.